En Es
Categories

Industry News

Labcorp to Spin Off Clinical Development Business

By Labmedica International staff writers
31 Jul 2022

Image: Labcorp has announced its intent to spin off its Clinical Development (CDCS) business (Photo courtesy of Labcorp)

LabCorp Diagnostics (Burlington, NC, USA) has announced that its board of directors has authorized the company to pursue a spin-off of its wholly owned Clinical Development business to shareholders through a tax-free transaction.


The planned spin-off will result in two independent, publicly traded companies, each poised for strong, sustainable growth:



  • Labcorp: A leading global laboratory business comprising the Company’s routine and esoteric labs, central labs and early development research labs, all of which are leaders with deep scientific expertise, vast health data and insights, and an extensive, advanced global laboratory network.

  • The Clinical Development Business: A leading, global Contract Research Organization (CRO) providing Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations.


The planned spin-off is expected to provide each company with:



  • Strengthened strategic flexibility and operational focus to pursue specific market opportunities and better meet customer needs.

  • Focused capital structures and capital allocation strategies to drive innovation and growth.

  • A more targeted investment opportunity for different investor bases.


Labcorp will remain a global leader advancing healthcare through science, innovation and technology with deep scientific expertise, vast health data and insights, and an extensive, advanced global laboratory network. Together, its lab-based businesses will create a cohesive, global provider of laboratory-focused services with complementary resources operating at scale and a diverse customer base. Following the planned spin-off, the business will be positioned to:



  • Invest in R&D and innovation to develop and launch diagnostic advancements globally in key areas including oncology, Alzheimer's, autoimmune and liver disease through organic and inorganic opportunities.

  • Bring together its global health and patient data and provide insights to enable customers to advance innovation.

  • Utilize its worldwide laboratory network to serve a broad, growing and global customer base including pharmaceutical and biotechnology companies, physicians, health systems, consumers, and other start-ups and labs who require lab services or diagnostic testing.

  • Launch innovative tests globally, providing patients, physicians, health systems and pharmaceutical companies with access to Labcorp’s advanced science, technology and diagnostic capabilities.


The Clinical Development business will continue to be a leading global provider of Phase I-IV clinical trial, market access and technology solutions to both large and emerging pharmaceutical and biotechnology organizations. Following the planned spin-off, the business will be positioned to:



  • Capitalize on growth opportunities across Phases I-IV clinical trials and extend its leadership in oncology, cell and gene therapy, rare disease, and other emerging therapeutic areas.

  • Increase agility with large pharmaceutical and biotechnology clients to better serve customers and advance life-saving therapies.

  • Retain access to Labcorp’s vast health and clinical data set through an arrangement which will enable it to provide enhanced trial execution and a differentiated value proposition.

  • Continue to invest in capabilities, technologies, diverse talent and innovation to enhance trial execution and better serve all of its customers.

  • Implement a capital structure that is tailored to support its growth strategy and enhance stakeholder value.


“Spinning off the Clinical Development business will benefit customers and shareholders by creating two standalone businesses that are poised to accelerate growth and focus resources on distinct strategic priorities, customer needs and value creation," said Adam Schechter, chairman and CEO of Labcorp. “Our shareholders will be able to participate in the upside potential of two market-leading businesses in the global healthcare sector, each of which will be well-capitalized and positioned to generate sustainable growth with strong free cash flows and attractive returns. Our customers will continue to have access to our full range of capabilities with the same quality and seamless delivery of services they have come to expect from our teams. Today is a testament to our long history of growth through innovation and track record of delivering on our mission to improve health and improve lives.”


Related Links:
LabCorp Diagnostics 



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

27 Sep 2022
Mindray Showcases Hematology Innovations at ISLH 2022
Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations in Laboratory Hematology (ISLH 2022) held between September 8-10 in Bologna, Italy.
Read More
23 Sep 2022
Parker Labs Partners with Tristel to Deliver Ultrasound Disinfectant for U.S. Market
Parker Laboratories Inc. (Fairfield, NJ, USA) has entered a commercial partnership with Tristel plc (Newmarket, UK) to manufacture and distribute the company's disinfectant foams for U.S. markets.
Read More
19 Sep 2022
Pluslife and FIND Set Collaborate to Empower LMICs with Next-Gen POC Molecular Testing in Women’s Healthcare
Guangzhou Pluslife Biotechnology (Pluslife, Guangzhou, China) and the Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) have entered into a strategic collaboration to support low- and middle-income countries (LMICs) in the development of diagnostic tools for women’s healthcare by providing access to next generation point of care (POC) molecular testing technology.
Read More
19 Sep 2022
RSNA 2022 to Showcase Latest Technologies for Advancing Patient Care
The Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) has announced Technical Exhibits highlights for their 108th Scientific Assembly and Annual Meeting (RSNA 2022) held in Chicago at McCormick Place, Nov. 27 – Dec. 1.
Read More
16 Sep 2022
International Hospital Federation Awards 2022 Finalists Announced
The International Hospital Federation (IHF; Geneva, Switzerland) has announced the finalists of the IHF Awards 2022 after scoring entries in seven categories.
Read More
16 Sep 2022
Intelerad Acquires Life Image to Create World’s Largest Medical Image Exchange Network
Intelerad Medical Systems (Raleigh, NC, USA), a leading global provider of enterprise imaging solutions, has acquired Life Image (Newton, MA, USA), one of the largest image exchange networks of curated clinical and imaging data, creating the largest medical image exchange network in the world and laying the groundwork for the elimination of costly CDs as the primary means of image transfer.
Read More
13 Sep 2022
Global Diagnostic Labs Market Driven by Increased POCT Testing and Smart Portable Devices
The global diagnostic labs market is projected grow at a CAGR of 8.3% from over USD 297 billion in 2021 to more than USD 514 billion by 2028, driven by the increasing prevalence of chronic diseases, growing use of POC diagnostics, and rising healthcare expenditures.
Read More
12 Sep 2022
ECR 2023 Now Set to Take Place from 1-5 March in Vienna
The European Society of Radiology (ESR, Vienna, Austria) has announced that the European Congress of Radiology (ECR) 2023 will now take place on March 1-5, 2023 in Vienna.
Read More
09 Sep 2022
Global PCR and Real-Time PCR Testing Market Driven by Need for Early Disease Detection
The global PCR and real time PCR testing market is expected to grow at a CAGR of 6.2% from USD 18.5 billion in 2021 to USD 19.64 billion in 2022 and further grow to USD 24.61 billion in 2026 at a CAGR of 5.8%.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions